Results 31 to 40 of about 518,936 (262)

Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A‐Rearranged ALL

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Adding blinatumomab to standard chemotherapy for infants with KMT2A‐rearranged acute B‐cell lymphoblastic leukemia (KMT2A‐r B‐ALL) improves outcomes. Although blinatumomab impairs immunoglobulin G (lgG) production, increasing infection susceptibility, IgG recovery remains poorly understood.
Miguel Vieira Martins, Paola de Lorenzo, Rishi S. Kotecha, Andishe Attarbaschi, Gabriele Escherich, Karsten Nysom, Jan Stary, Alina Ferster, Benoit Brethon, Franco Locatelli, Martin Schrappe, Peggy E. Scholte‐van Houtem, Maria G. Valsecchi, Rob Pieters, Inge M. van der Sluis   +14 more
wiley   +1 more source

Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay

Haematologica, 2020
Peripheral T-cell lymphoma comprises a heterogeneous group of mature non-Hodgkin lymphomas. Their diagnosis is challenging, with up to 30% of cases remaining unclassifiable and referred to as “not otherwise specified”.
Fanny Drieux, Philippe Ruminy, Ahmad Abdel-Sater, François Lemonnier, Pierre-Julien Viailly, Virginie Fataccioli, Vinciane Marchand, Bettina Bisig, Audrey Letourneau, Marie Parrens, Céline Bossard, Julie Bruneau, Pamela Dobay, Liana Veresezan, Aurélie Dupuy, Anaïs Pujals, Cyrielle Robe, Nouhoum Sako, Christiane Copie-Bergman, Marie-Hélène Delfau-Larue, Jean-Michel Picquenot, Hervé Tilly, Richard Delarue, Fabrice Jardin, Laurence de Leval, Philippe Gaulard   +25 more
doaj   +1 more source

Next-Generation Immunotherapies to Improve Anticancer Immunity

Frontiers in Pharmacology, 2021
Checkpoint inhibitors are widely used immunotherapies for advanced cancer. Nonetheless, checkpoint inhibitors have a relatively low response rate, work in a limited range of cancers, and have some unignorable side effects.
Yaoyao Shi, Katarzyna Tomczak, June Li, Joshua K. Ochieng, Younghee Lee, Cara Haymaker   +5 more
doaj   +1 more source

Natural Killer Cells in Paediatric Soft Tissue Sarcomas: A Systematic Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Paediatric soft tissue sarcomas (pSTS) are a rare and heterogeneous group of malignant tumours arising in tissues of mesenchymal origin. The role of natural killer (NK) cells in pSTS remains poorly understood, with evidence fragmented across small preclinical studies and early‐phase clinical trials.
Raya Dean, Lara V. Graham, Christina Putnam, Rosa Gomes Alves Martins, Daniel T. Harding, Tim J. Underwood, Zoë S. Walters, Matthew D. Blunt   +7 more
wiley   +1 more source

Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley, Ryleigh Krueger, Kellie Joyce, James Stanley, Mary Waskerwitz‐Freyer, Marielle Klunder, David J. Hoogstra   +6 more
wiley   +1 more source

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz, Martin Ebinger, Michaela Döring, Markus Mezger, Ursula Holzer, Rupert Handgretinger, Peter Lang, Manon Queudeville   +7 more
wiley   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Characterization of atypical T cells generated during ex vivo expansion process for T cell-based adoptive immunotherapy

Frontiers in Immunology
Engineered T cell-based adoptive immunotherapies met promising success for the treatment of hematological malignancies. Nevertheless, major hurdles remain to be overcome regarding the management of relapses and the translation to solid tumor settings ...
Patricia Mercier-Letondal, Abhishek Kumar, Chrystel Marton, Francis Bonnefoy, Maxime Fredon, Laura Boullerot, Barbara Dehecq, Olivier Adotévi, Olivier Adotévi, Yann Godet, Jeanne Galaine   +10 more
doaj   +1 more source

In vivo OVA-specific Cytotoxic CD8+ T Cell Killing Assay

Bio-Protocol, 2016
Cytotoxic CD8+ T cells are responsible for the lysis of cells expressing peptides associated with MHC class I molecules and derived from infection with a pathogen or from mutated antigens.
Nada Chaoul, Catherine Fayolle, Claude Leclerc   +2 more
doaj   +1 more source

Reciprocal control of viral infection and phosphoinositide dynamics

FEBS Letters, EarlyView.
Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley   +1 more source